BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3934 related articles for article (PubMed ID: 23046836)

  • 1. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
    Hafner J
    J Phys Condens Matter; 2008 Feb; 20(6):060301. PubMed ID: 21693862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A proposal for reforming psychologists' training in France and in the European Union].
    Bouchard JP
    Encephale; 2009 Feb; 35(1):18-24. PubMed ID: 19250989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
    Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
    Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring opportunities for collaboration between the corporate sector and the dental education community.
    Alexander D; Clarkson J; Buchanan R; Chadwick G; Chesters R; Drisko CL; Douglass CW; Farrell L; Fletcher K; Makoni F; Monaco M; Nordquist B; Park NI; Riggs S; Schou L; Smales FC; Stamm JW; Toh CG; Volpe T; Ward P; Warren P
    Eur J Dent Educ; 2008 Feb; 12 Suppl 1():64-73. PubMed ID: 18289269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategic funding priorities in the pharmaceutical sciences allied to Quality by Design (QbD) and Process Analytical Technology (PAT).
    Aksu B; De Beer T; Folestad S; Ketolainen J; Lindén H; Lopes JA; de Matas M; Oostra W; Rantanen J; Weimer M
    Eur J Pharm Sci; 2012 Sep; 47(2):402-5. PubMed ID: 22749874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public-private partnership models in France and in Europe.
    Demotes-Mainard J; Canet E; Segard L
    Therapie; 2006; 61(4):325-34, 313-23. PubMed ID: 17124948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public-private partnerships in translational medicine: concepts and practical examples.
    Luijten PR; van Dongen GA; Moonen CT; Storm G; Crommelin DJ
    J Control Release; 2012 Jul; 161(2):416-21. PubMed ID: 22465390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Innovative Medicine Initiative (IMI)].
    Bril A; Canet E
    Med Sci (Paris); 2008 Oct; 24(10):885-90. PubMed ID: 18950588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community health outreach program of the Chad-Cameroon petroleum development and pipeline project.
    Utzinger J; Wyss K; Moto DD; Tanner M; Singer BH
    Clin Occup Environ Med; 2004 Feb; 4(1):9-26. PubMed ID: 15043361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New safe medicines faster: A proposal for a key action within the European union's 6th framework programme.
    Bjerrum OJ
    Pharmacol Toxicol; 2000; 86 Suppl 1():23-6. PubMed ID: 10905750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enabling Europe to innovate.
    Dearing A
    Science; 2007 Jan; 315(5810):344-7. PubMed ID: 17234939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New pathway for qualification of novel methodologies in the European Medicines Agency.
    Manolis E; Vamvakas S; Isaac M
    Proteomics Clin Appl; 2011 Jun; 5(5-6):248-55. PubMed ID: 21538915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences.
    Mochel JP; Tyden E; Hellmann K; Vendrig JC; Şenel S; Dencker L; Cristina RT; Linden H; Schmerold I
    J Vet Pharmacol Ther; 2018 Jun; 41(3):378-383. PubMed ID: 29266320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 197.